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Abstract
The classic chronic myeloproliferative neoplasms (MPN) include different 
significant  challenges  for  their  optimal  diagnosis,  treatment  and  overall  management. 
Polycythemia Vera and Essential Thrombocythemia are the most common among chronic 
myeloproliferative  neoplasms  (MPNs);  major  causes  of  morbidity  and  mo
represented  by  arterial  and  venous  thrombosis,  as  well  as  evolution  to  myelofibrosis  or 
transformation  to  acute  leukemia.  However,  survival  is  only  minimally  affected.  Therapy 
aims  at  reducing  the  rate  of  thrombosis  without  increasing  the  risk 
transformation which could be caused by exposure to cytotoxic drugs. On the other hand, 
survival is significantly reduced in primary myelofibrosis, and the clinical manifestations may 
be disabling. In the absence of therapies with the potent
risk-oriented approach is employed for stratifying patients to the most appropriate, currently 
available, therapeutic options. In this brief review, we will discuss some of the key issues that 
can  arise  along  the  clinical  course  of  MPNs  and  require  an  integrated,  strictly  patient
oriented, approach.
Introduction:  The  approach  to  a  patient  suffering 
from  a Philadelphia-chromosome  negative, classic 
Myeloproliferative  Neoplasm  (MPN)
mostly of a strict hematological pertinence or can 
require  a  complex,  multidisciplinary  approach  in 
cases where the disease has an aggressive course or 
presents  or  evolves  with  complications (
There  are  obvious  differences  in  clinical 
presentation  that  are  related  to  the  unique  MPN 
entities,  the  worse  being  primary  myelofibrosis 
; Open Journal System 
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The classic chronic myeloproliferative neoplasms (MPN) include different entities that pose 
significant  challenges  for  their  optimal  diagnosis,  treatment  and  overall  management. 
Polycythemia Vera and Essential Thrombocythemia are the most common among chronic 
myeloproliferative  neoplasms  (MPNs);  major  causes  of  morbidity  and  mo
represented  by  arterial  and  venous  thrombosis,  as  well  as  evolution  to  myelofibrosis  or 
transformation  to  acute  leukemia.  However,  survival  is  only  minimally  affected.  Therapy 
aims  at  reducing  the  rate  of  thrombosis  without  increasing  the  risk 
transformation which could be caused by exposure to cytotoxic drugs. On the other hand, 
survival is significantly reduced in primary myelofibrosis, and the clinical manifestations may 
be disabling. In the absence of therapies with the potential of curing the disease, a careful 
oriented approach is employed for stratifying patients to the most appropriate, currently 
available, therapeutic options. In this brief review, we will discuss some of the key issues that 
al  course  of  MPNs  and  require  an  integrated,  strictly  patient
The  approach  to  a  patient  suffering 
chromosome negative,  classic 
Myeloproliferative  Neoplasm  (MPN)
1 can  be 
mostly of a strict hematological pertinence or can 
require  a  complex,  multidisciplinary  approach  in 
disease has an aggressive course or 
presents  or  evolves  with  complications  (Table  1). 
There  are  obvious  differences  in  clinical 
presentation  that  are  related  to  the  unique  MPN 
entities,  the  worse  being  primary  myelofibrosis 
(PMF);  however,  it  must  be  kept
protean  clinical  issues  are  largely  and  often 
unpredictably  patient-related.  However,  from  a 
clinical  point  of  view,  the  most  challenging 
consideration  for  the  physician  is  that  while  the 
overall survival of PV or ET patients may be only 
marginally  affected  by  the  disease,  survival  may 
range from a few months to an excess of a decade in 
PMF  patients.  The  main  complications  of 
polycythemia  vera  (PV)  and  essential
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entities that pose 
significant  challenges  for  their  optimal  diagnosis,  treatment  and  overall  management. 
Polycythemia Vera and Essential Thrombocythemia are the most common among chronic 
myeloproliferative  neoplasms  (MPNs);  major  causes  of  morbidity  and  mortality  are 
represented  by  arterial  and  venous  thrombosis,  as  well  as  evolution  to  myelofibrosis  or 
transformation  to  acute  leukemia.  However,  survival  is  only  minimally  affected.  Therapy 
aims  at  reducing  the  rate  of  thrombosis  without  increasing  the  risk  of  hematologic 
transformation which could be caused by exposure to cytotoxic drugs. On the other hand, 
survival is significantly reduced in primary myelofibrosis, and the clinical manifestations may 
ial of curing the disease, a careful 
oriented approach is employed for stratifying patients to the most appropriate, currently 
available, therapeutic options. In this brief review, we will discuss some of the key issues that 
al  course  of  MPNs  and  require  an  integrated,  strictly  patient-
(PMF);  however,  it  must  be  kept in  mind  that 
protean  clinical  issues  are  largely  and  often 
related.  However,  from  a 
clinical  point  of  view,  the  most  challenging 
consideration  for  the  physician  is  that  while  the 
overall survival of PV or ET patients may be only 
inally  affected  by  the  disease,  survival  may 
range from a few months to an excess of a decade in 
PMF  patients.  The  main  complications  of 
polycythemia  vera  (PV)  and  essentialMedit J Hemat Infect Dis 2010; 2(2): Open Journal System
Table 1. Some of the key issues in the management of MPN patients that require integrated skills.
Polycythemia Vera / Essential Thrombocythemia Myelofibrosis
 Prevention of vascular complication 
 Ongoing treatment of prior thrombotic events
 Control of myeloproliferation 
 Control of splenomegaly
 Symptomatic control of disease manifestations 
 Treatment of anemia and cytopenias 
 Control of splenomegaly 
 Control of myeloproliferation 
 Prevention of vascular complication
 Symptomatic control of disease manifestations
 Palliative therapy versus HSCT
 Familial forms and discussion of genetic predisposition
 Pregnancy management and counseling
 Choice between no therapy, conventional therapy, experimental therapy
thrombocythemia (ET) are cardiovascular in nature 
and constitute the leading cause of death.
2 As such, 
they  may  require  counseling  of  specialists  from 
different  fields  including  cardiologists,  vascular 
surgeons, gastroenterologists (for the manifestations 
and  complications  of  splancnic  vein  thromboses), 
radiologists,  and  experts  in  anticoagulation 
therapy.
3 A  young  lady  with  ET  who  plans  to 
become pregnant, or is expected to deliver, poses 
specific  problems  in  antithrombotic  treatment 
during  pregnancy  and  in  the  immediate  post-
delivery  period,  as  well  as  requires  careful 
obstetrician  management.
4 Furthermore, 
opportunity  about  a  myelosuppressive  treatment 
before conception and during pregnancy should be 
accurately discussed in case a woman is considered 
at  high-risk  because  of  the  characteristics  of  her 
disease  or  a  history  of  previous  abortions. 
Therapeutic  decisions  regarding  massive  and 
symptomatic  splenomegaly  in  MF,  and  more 
infrequently  in  PV  or  ET,  may  involve  the 
hematologist,  the  surgeon,  as  well  the 
radiotherapist.
5 Leukemic  transformation  is 
associated  with  a  very  dismal  outcome  with 
conventional chemotherapeutic approaches because 
of intrinsic characteristics of the disease as well as 
the  almost  universal  presence  of  comorbidities  in 
older  patients;  therefore,  decisions  about  choice 
between  intensive  chemotherapy,  a  smoother 
therapeutic approach, supportive treatment only, as 
well as counseling for the end-of-life decisions or 
hospice treatment  need to  be  taken by discussing 
with  the  patients,  relatives  and  colleagues  from 
different  medical  specialites.
6 Cutaneous 
complications  from  cytotoxic  therapy  with 
hydroxyurea  (leg  ulcers)  represent  a  relatively 
common  side  effect  of  therapy  and  constitute  a 
therapeutic  dilemma  that  requires  dermatologist’s 
approach,  nurse’s  care,  and  eventually  additional 
specialists  (experts  in  hyperbaric  therapy, 
reconstructive surgeon). Recent improvement in the 
use  of  hematopoietic  stem  cell  transplantation  in 
patients  with  MF,  and  the  availability  of  novel 
drugs, that  include JAK2 inhibitors,
7 inhibitors of
histone  deacethylases
8 and  possibly  others,  will 
probably result  in  a  modification  of  our  current 
approach to MPNs in the near future, making the 
management of these disorders even more complex 
but, hopefully, more effective possibly leading to a 
cure.  
In this review we will briefly discuss four issues 
that  are:  genetic  counseling,  the  management  of 
pregnancy in a woman affected by MPN, how to 
face a massively enlarged spleen in myelofibrosis, 
and the criteria for choosing between conventional 
and experimental therapy.
Genetic  counseling:  MPNs  are  not  hereditary 
disorders, and as such there has been no indication 
until now to refer patients to an expert of human 
genetics. However, the fact that familial forms of 
MPNs, whose existence has been long known, are 
discovered  more  and  more  frequently  (their  rate 
probably being linearly dependent on the accuracy 
the existence of MPNs in the family is searched for 
by  the  referring  hematologist),  and  recent 
discoveries  about  JAK2  46/1-GGCC  predisposing 
haplotype,  combined  with  the  diffusion  of  these 
information  through  specialized  and  non-
specialized web sites or the print, have all increased 
awareness by the patients, especially youngest. So, 
we can expect that the question “..will I transmit the 
disease to my sons?”  is increasingly proffered to 
physician  by  newly  diagnosed  MPN  patients.  At 
this  time  speaking,  MPNs  continue  to  be  purely 
acquired  disorders,  with  no  evidence  of  germline 
transmission, no need of genetic counseling, and no 
need, on the hematologist’s side, to suggest testing 
familial  members  with  either  simple  (automated 
blood cell count) or complex (molecular analysis of 
JAK2 or similar mutations) laboratory approaches. 
It  is  key  to  avoid  generating  unjustified  and Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
unethical  “mind  storms”  in  the  patients  and  their 
relatives  by  an  inappropriate  usage  of  the  novel 
information  deriving  from  our  increasing 
knowledge of the molecular complexity of MPNs.
How to manage pregnancy: The opportunity for a 
physician  to  deal  with  a  pregnant  woman  is 
definitely more common in ET than in PV due to 
younger  age.  There  is  no  controlled  study 
concerning  management  strategies,  and 
recommendations only reflect experts’ opinions.
9,10
About seventy per cent of 461 pregnancies reported 
in ET women ended with successful live.
11 On the 
other  hand,  the  incidence  of  major  maternal 
complications was significantly higher (44%) in the 
18 PV patients included in one single-centre study
12
as  compared  to  ET  (about  5%).  Interestingly,  an 
association  of  JAK2V617F  mutational  status  with 
greater  occurrence  of  pregnancy  complications  in 
ET has been described.
13 It is key to identify a “at 
high-risk pregnancy”, such as in a woman who had 
history of previous thrombosis or presented severe 
complications  during  previous  pregnancies.  The 
latter include 3 or more first-trimester or 1 or more 
third-trimester losses; a previous birth weight less 
than  the  5
th centile  of  gestation;  development  of 
symptoms  of  pre-eclampsia;  intrauterine  death  or 
stillbirth.  In  fact,    a  “low-risk  pregnancy”  in  ET 
could be managed with observation only a part for 
maintaining hematocrit level lower than 45% in a 
few  cases  where  the  physiologic  decrease  of 
hemoglobin  levels  does  not  happen.  There  is  no 
clear  indication  to  support  prophylactic  low-dose 
aspirin  in  the  absence  of  microcirculatory 
symptoms in ET,  while all patients with PV should 
receive aspirin during pregnancy until about 1 week 
before  planned  delivery.  However,  in  absence  of 
controlled  studies,  some  authors  consider 
appropriate the administration  of low-dose aspirin 
even  in  “low  risk”  ET.  The  presence  of  classic 
cardiovascular risk factors in these patients, such as 
obesity  or  bed  rest,  can  be  a  issue  for  choosing 
LMWH prophylaxis instead of aspirin. The lack of 
obvious  correlation  between  thrombocytosis  and 
pregnancy  complication  makes  correction  of 
platelet count not  a relevant target for therapy, also 
considering  that  platelet  count  often  reaches  and 
maintains  normal  levels  throughout  pregnancy. 
When  there  is  the  need  to  control 
myeloproliferation interferon-alpha is the only drug 
recommended  because  its  lack  of  teratogenic 
properties. Neither HU nor anagrelide can be used 
during pregnancy. In the absence of any evidence-
based  information in the  literature, and  only as  a 
cautionary attitude, we suggest at least a six-month 
period wash-out from either drug in case of planned 
conception; however, it should be stressed that fetal 
abnormalities have been reported only in one out of 
60  pregnancies  that  were  successfully  completed 
under  HU.
12 Low  molecular  weight  heparin 
(LMWH) is  recommended  after delivery until  six 
weeks  postpartum  to  prevent  venous 
throemboembolism;  eventually,  prophylactic 
LMWH could be started 1-2 weeks before expected 
labour  and  stopped  about  12  hours  before.  Some 
experts also consider the combined use of aspirin 
and  LMWH  throughout  pregnancy  and  for  six 
weeks after delivery in high-risk ET patients and in 
all  PV  women.
10 Thus,  the  management  of 
pregnancy is a MPN woman is a  complex issue that 
requires  interactions  of  the  hematologist  with  the 
couple to counsel  about the best approach and to 
reassure  the  woman  about  potential  risks  and 
benefits of no therapy versus therapy; and with the 
gynecologist  and  obstetrician  for  an  accurate 
follow-up (it should not be undermined that this is 
anyway a “at risk” pregnancy compared to control 
population). We have to reassure the woman who 
wants to become a mother that this is feasible and 
low-risk, and do our best to make her feeling helped 
and  safe  at  any  time  point  during  pregnancy  and 
delivery.   There  are also some grey areas strictly 
connected  with  the  issue  of  pregnancy  in  MPNs; 
these  concern  counseling  about  hormonal  therapy 
for  contraception  (that  should  be  discourages  as 
possible), about the risk of fetal defects in the case 
conception happened whilst on therapy, and finally 
also about the potential risks associated with the use 
of  cytotoxic  drugs  by  the  father.  Unfortunately, 
there is little to no experience at this regard that can 
help  making  recommendations,  so  that only 
prudent, individualized and shared approach can be 
employed.
How  to  face  massive splenomegaly  in 
myelofibrosis: Splenomegaly can be found in all the 
MPNs, but it is a main complaint of patients with 
myelofibrosis  as  the  manifestation  of  massive 
extramedullary  hematopoiesis  that  results  largely 
from the substitution of hematopoietic tissue with 
reticulin  and  collagen  fibers  in  the  bone  marrow. 
Splenomegaly causes local problems (early saxiety, 
manifestations due to  local compression on organ 
and vessels) and contributes to systemic symptoms, 
particularly  cachexia,  and  hematological 
abnormalities  due  to  sequestration  of  red  blood 
cells,  granulocytes  and  platelets.  An  excellent 
critical review of how to manage splenectomy has 
been published recently.
5 No conventional drug is 
effective against huge spleen enlargement, although Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
Table 2. Indications and outcome of splenectomy for massive 
splenomegaly  in  myelofibrosis.  Numerical  values  indicate 
proportion of the patients. From Mesa
5.
Indications
 Symptoms ascribable to local compression (50%)
 Refractory, transfusion-dependent anemia (25%)
 Refractory thrombocytopenia (15%)
 Portal hyperthension (10%)
Complications of surgery
 Overall morbidity (30-40%)
 Hemorrhage (15%)
 Thrombosis (10-15%)
 Fatalities (7-10%)
Improvement rate
 Symptoms ascribable to local compression: 50%
 Anemia: 50%
 Thrombocytopenia: 30%
 Portal hyperthension: 40%
Long-term outcome 
 Leukemia: 10-15%
 Progressive hepatomegaly: 10-15%
hydroxyurea may help in the early phase of disease. 
Splenectomy  carries  a  considerable  risk  during 
surgery  and  in  the  post-surgery  phase  due  to 
vascular  complications,  hemorrhages,  infections, 
and  myeloproliferative  reactions  (Table  2). 
Splenomegaly  can  also  represent  a  negative 
prognostic  factor  for  patients  undergoing 
hematopoietic  stem  cell  transplantation.
14 Thus, 
managing  massive  splenomegaly  in  myelofibrosis 
requires an integrated  experienced team involving 
the  referring  hematologist,  the  radiotherapist,  the 
surgeon,  a  physician  experienced  in  managing
splancnic  thrombotic  complications  after  surgery, 
and eventually an hematologist with experience in 
transplanting myelofibrosis patients. But, first of all, 
a comprehensive discussion with the patient of the 
indications, risk and expected benefits and possible 
risks is mandatory.
Choosing  between  conventional  and 
experimental  therapies:  The  management  of  ET 
and PV has been traditionally problematic because 
of  the lack of robust evidence-based management 
guidelines. Factors for identifying high-risk patients 
who deserve a more aggressive treatment have been 
discovered  and  validated  in  large  clinical  studies, 
and  novel  ones  are  under  strict  scrutiny  more 
recently.
1 The former are represented by older age 
and a previous history of vascular events, the latter 
are the JAK2V617F mutational status or burden and 
leukocytosis.  The  widely  employed  drug  in  high 
risk patients is hydroxyurea in association with anti-
platelet  agents;  the  approach  successfully  reduces 
(but  does  not  eliminate)  the  risk  of  major 
thrombosis,  but  whether  it  is  able  to  modify  the 
course of disease is questionable. Although the rate 
of leukemia transformation is probably not different 
from control patient populations, use of a cytotoxic 
drug  is  preferably  to  avoid  in  younger  patients. 
Also, although the rate of resistance/intolerance to 
hydroxyurea  in  probably  less  than10%  of  all 
patients, in some instances the treatment has to be 
shifted  towards  other  cytotoxic  agents,  with  a 
measurable  increase  in  the  risk  of  leukemic 
transformation.  The  scenario  in  therapeutic 
armamentarium for MPNs is dramatically changing 
(Table  3),  and  in  the  next  few  years  it  will  be 
possible  that  a  number  of  clinical  trials  will  be 
activated  hopefully  providing  new  avenues  for 
improving  the  outcome,  the  quality  of  life,  and 
reducing  complications  associated  with  these 
disorders.
Table 3. Novel drugs on the pipeline for MPNs.
Drug class Molecules Main targets / disease References
JAK2 inhibitors INCB 018424
TG101348
Splenomegaly, constitutional symptoms (mainly MF, 
potentially PV or ET)
[15]
[16]
Immunomodulating agents Lenalidomide, 
Pomalidomide Anemia   (MF) [17]
[18]
Interferons PEG-
interferon-a Mainly PV and ET, preliminary data in early MF [19]
Histone deacethylase inhibitors Givinostat Mainly PV [20]Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
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